North America small molecule active pharmaceutical ingredient (API) market is expected to grow by 5.7% annually in the forecast period and reach $90.22 billion by 2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic.
Highlighted with 26 tables and 49 figures, this 107-page report "North America Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire North America small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country.

Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
- Synthetic API
o Branded Synthetic API
o Generic Synthetic API
- Semi-synthetic API
- Natural Origin

Based on Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
- Standard API
- High Potency API (HPAPI)
o Branded HPAPI
o Generic HPAPI

Based on Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
- Infectious Diseases
- Oncology
- Ophthalmology
- Cardiovascular Disorders
- Central Nervous System
- Respiratory Disorders
- Metabolic Diseases
- Other Applications

Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
o Clinical Use
o Commercial Use

Based on Manufacturer Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
- Pharmaceutical Companies
- CMOs

Geographically, the following national/local markets are fully investigated:
- U.S.
- Canada
- Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent, Inc.
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)